BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

NBE-Therapeutics appoints Dr. Anthony Tolcher on Scientific Advisory Board

16 November 2018 | News

Dr. Tolcher is a Board certified Medical Oncologist from San Antonio, TX, U.S.A., with significant experience in performing early-stage clinical trials with Antibody Drug Conjugates (ADCs).



NBE Therapeutics AG, a biopharmaceutical company developing next-generation immune-stimulatory antibody-drug conjugates (iADCs™) for improved cancer therapy, today announces the appointment of Dr. Anthony Tolcher to NBE's Scientific Advisory Board (SAB).

Dr. Tolcher is a Board certified Medical Oncologist from San Antonio, TX, U.S.A., with significant experience in performing early-stage clinical trials with Antibody Drug Conjugates (ADCs). Dr. Tolcher was previously co-founder and a leading member of START (South Texas Accelerated Research Therapeutics), managing a network of global clinical trial centers across the U.S., Europe and Asia.

Currently, Dr. Tolcher is founder and CEO of NEXT-Oncology in San Antonio, TX, U.S.A, a clinical research organization dedicated to advance highly innovative cancer medicines to first-in-human clinical trials. Dr. Tolcher is a renowned key opinion leader in the field of clinical development of ADCs and advises NBE-Therapeutics on its strategies to advance NBE's late-stage preclinical development pipeline of iADCs™ to early stage clinical validation in cancer patients (phaseI/II clinical trials).

Dr. Tolcher said**,** "Having performed a comprehensive review of NBE's late-stage preclinical data for NBE-Therapeutic's iADC programs, and in particular NBE's lead program NBE-002 targeting ROR-1 to treat difficult solid tumors, like triple negative breast cancer (TNBC), sarcoma and lung cancer, I am very excited to support NBE-Therapeutics to advance its iADC programs to the clinic. There are tremendous opportunities of NBE's platform to lead to advancements in the treatment of many cancers and as a combination with current and future immune checkpoint inhibitors."